|  |  |
| --- | --- |
| **ONCOPOLE *EMC2******Équipes multi-institutionnelles*** ***contre le cancer******Multi-institutional teams against cancer*** | **EVALUATION REPORT**Deadline to complete the review:  |

☐ Reviewer 1 ☐ Reviewer 2

|  |
| --- |
| **RESEARCH PROJECT TITLE** |
|  |

|  |
| --- |
| **PRINCIPAL INVESTIGATOR(S) IDENTIFICATION** |
|  |
| **Principal Investigator #1 (Project leader)** |
| Name:  | First name(s):  |
| Institution: |
| **Principal Investigator #2** |
| Name:  | First name(s):  |
| Institution: |
| **Principal Investigator #3**  |
| Name: | First name(s): |
| Institution: |

|  |
| --- |
| **Instructions :** *Please comment and give your Appreciation SCORE based on the CRITERIA defined FOR each SECTION**Please give your FINAL SCORE ON THE LAST PAGE (REFER TO the provided scale)* |

|  |
| --- |
| **PROGRAM’S OBJECTIVE** |
| The mission of the Oncopole is to act as a catalyst by investing to maximize Québec’s cancer research and innovation, mobilize the best research teams, coordinate efforts and attract more investments. Ultimately, Oncopole aims to reduce the incidence of cancer, optimize care, and improve treatment performance as well as cancer patients’ survival and quality of life. ([**https://oncopole.ca/?lang=en**](https://oncopole.ca/?lang=en))This first call for proposals aims to finance cooperative and structuring research projects that will capitalize on Québec’s networks, platforms, resources, and existing strengths and expertise. The funded projects will have to potentiate these assets and thus increase Québec's competitiveness at national and international levels. The program can fund existing teams or support the creation of new teams around promising research areas. Projects must focus on **interdisciplinarity** to: * Bring researchers from various research environments, disciplines and areas of expertise to work together using a wide range of approaches and cutting-edge technologies
* Be structured in such a way as to bring an original added value that researchers, funded individually, could not reach by themselves

Interdisciplinary research projects may focus on prevention, diagnosis or treatment, and be at the stage of discovery, translational or preclinical research, early clinical research or evaluative research. Clinical trials that would normally only be funded by the industry are not eligible.The program is open to all types of cancer. Projects must be aligned to a clearly identified clinical need and will have to demonstrate the complementarity between the research team members and the added value of collaborations. A clear and well-defined plan for sharing resources, data and platforms will also be required. |

|  |
| --- |
| **SECTION A : scientific Excellence AND ORIGINALITY of the RESEARCH project** |
| **Global appreciation** | **/ 30** |
| **Comments on section B:** **Please comment on the following criteria :*** Compliance with the program’s objectives
* Coherence of the research strategy (integrated project), based on innovation and scientific excellence
* Unifying and structuring potential of the project for Québec
* Multi-institutional team composition
* Development, harmonization and pooling of the platforms and resources of the different partners
* Quality of proposed data and knowledge sharing mechanisms
* Clarity of scientific objectives
* Relevance of project interdisciplinarity
* Identification of the clinical need to which the project will respond, targeting cancer prevention, early detection, diagnosis, therapies or patient care

Alignment with more than one of the Oncopole areas of focus (Research, Valorization, Integration of Innovation, and Training and Awareness) is considered an asset. ([**https://oncopole.ca/?lang=en**](https://oncopole.ca/?lang=en)) |

|  |
| --- |
| **SECTION B: Research team – expertise and complementarity of the researchers** |
| **Global appreciation** | **/ 25** |
| **Comments on section B:** **Please comment the following criteria:*** Achievements and scientific level of the research team (track record, outreach at the Canadian and / or international level, etc.)
* Added value and synergy of collaborations
* Complementarity of expertise and interdisciplinarity
* Presence and level of involvement of early career researchers (7 years or less)
* Role in training young scientists and in increasing research capacity in oncology
* Quality of partnerships (and collaborators) outside of investigators
* Integration of patient (s), if relevant, is an asset
 |

|  |
| --- |
| **SECTION C: FEASIBILITY** |
| **Global appreciation** | **/ 20** |
| **Comments on section C:****Please comment on the following criteria :*** Scientific and technical feasibility of the project, choice of methods
* Accuracy, importance and rigor in defining the project’s structure, expected results and milestones
* Realistic timeline and relevance of monitoring indicators
* Effective use of existing resources from the different research institutions
 |

|  |
| --- |
| **SECTION D : IMPACTS AND KNOWLEDGE TRANSFER** |
| **Global appreciation** | **/25** |
| **Comments on section D:** **Please comment on the following criteria :*** Importance (quantitative when applicable) of the problem addressed and potential impact of the proposed approach to solve this challenge.
* Relevance of impact in the context of a long-term vision
* Development of new products, services, concepts, methodologies, practices, tools and resources that could be transferable to the community or industry
* Potential to attract subsequent funding, form new major partnerships and improve the competitiveness of Québec's ecosystem
* Proposed strategies to ensure that research results are used in the development and/or implementation of:
	+ Better treatments
	+ Better tools for diagnostic and prevention
	+ New healthcare policies or practices for patients
 |

|  |
| --- |
| **SECTION E: Budget**  |
| **Adequate** |[ ]  **Inadequate** |[ ]
| **Comments on section E:** **Please comment on the budget appropriateness and justifications. Leverage, if applicable, should bring direct value to the project to be considered as an asset.**  |

|  |
| --- |
| **SECTION F: ADDITIONAL COMMENTS**  |
|  |

|  |
| --- |
| **TOTAL SCORE** |
| **/ 100*****Score ≥ 75 = fundable*** | ***Exceptional*** | **95 -100** |
| ***Excellent*** | **85 - 94** |
| ***Very good*** | **75 - 84** |
| ***Good*** | **60 - 74** |
| ***Weak*** | **30 - 59** |
| ***Unacceptable*** | **0 – 29** |